Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - empagliflozin, quantity: 5 mg; metformin hydrochloride, quantity: 1000 mg - tablet, film coated - excipient ingredients: maize starch; copovidone; colloidal anhydrous silica; magnesium stearate; hypromellose; purified talc; iron oxide yellow; macrogol 400 - jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is appropriate (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties - clinical trials).,empagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see section 5.1 pharmacodynamic properties - clinical trials).,to prevent cardiovascular deaths, empagliflozin should be used in conjunction with other measures to reduce cardiovascular risk in line with the current standard of care.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - empagliflozin, quantity: 5 mg; metformin hydrochloride, quantity: 850 mg - tablet, film coated - excipient ingredients: maize starch; copovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 400 - jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is appropriate (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties - clinical trials).,empagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see section 5.1 pharmacodynamic properties - clinical trials).,to prevent cardiovascular deaths, empagliflozin should be used in conjunction with other measures to reduce cardiovascular risk in line with the current standard of care.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - empagliflozin, quantity: 5 mg; metformin hydrochloride, quantity: 500 mg - tablet, film coated - excipient ingredients: maize starch; copovidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 400 - jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and metformin is appropriate (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties - clinical trials).,empagliflozin is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease to reduce the risk of cardiovascular death (see section 5.1 pharmacodynamic properties - clinical trials).,to prevent cardiovascular deaths, empagliflozin should be used in conjunction with other measures to reduce cardiovascular risk in line with the current standard of care.

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 10 mg - kadian is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions ( 5.1 )] , reserve kadian for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - kadian is not indicated as an as-needed (prn) analgesic. kadian is contraindicated in patients with - significant respiratory depression [see warnings and pre cautions ( 5.2 )] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [s ee warnings and precautions ( 5.5 )] - concurrent use of m

United States - English - NLM (National Library of Medicine)

allergan, inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 10 mg - kadian is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use : - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions ( 5.1 )] , reserve kadian for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - kadian is not indicated as an as-needed (prn) analgesic. kadian is contraindicated in patients with:  - significant respiratory depression [see warnings and pre cautions ( 5.3 )] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [s ee warnings and precautions ( 5.6 )] - concurrent use

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - stiripentol, quantity: 500 mg - powder, oral - excipient ingredients: sodium starch glycollate type a; povidone; spray-dried liquid glucose; erythrosine; titanium dioxide; aspartame; carmellose; hyetellose; flavour - diacomit is indicated for adjunctive treatment of generalised tonic-clonic and clonic seizures associated with severe myoclonic epilepsy in infancy (smei, also known as dravet syndrome) in patients whose seizures are not adequately controlled with a benzodiazepine (usually clobazam) and valproate.

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - stiripentol, quantity: 250 mg - powder, oral - excipient ingredients: sodium starch glycollate type a; povidone; spray-dried liquid glucose; erythrosine; titanium dioxide; aspartame; carmellose; hyetellose; flavour - diacomit is indicated for adjunctive treatment of generalised tonic-clonic and clonic seizures associated with severe myoclonic epilepsy in infancy (smei, also known as dravet syndrome) in patients whose seizures are not adequately controlled with a benzodiazepine (usually clobazam) and valproate.

European Union - English - EMA (European Medicines Agency)

bayer ag - finerenone - renal insufficiency, chronic; diabetes mellitus, type 2 - agents acting on the renin-angiotensin system - kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.

Israel - English - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride; glucose; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - solution for peritoneal dialysis - glucose 38.6 g/l; lactic acid as sodium 4.5 g/l; glucose as monohydrate 42.5 g/l; magnesium chloride 0.051 g/l; sodium chloride 5.4 g/l; calcium chloride 0.184 g/l - isotonic solutions - indicated whenever peritoneal dialysis is employed including acute and chronic renal failure, severe water retention, electrolyte disorders, drug intoxication.

Israel - English - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride; glucose; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - solution for peritoneal dialysis - lactic acid as sodium 4.5 g/l; sodium chloride 5.4 g/l; glucose 22.7 g/l; calcium chloride 0.184 g/l; magnesium chloride 0.051 g/l; glucose as monohydrate 25 g/l - indicated whenever peritoneal dialysis is employed including acute and chronic renal failure, severe water retention, electrolyte disorders, drug intoxication.